(Boursier.com) — Johnson & Johnson, an American pharmaceutical and medical giant, has agreed to the acquisition of the Ambrx Biopharma group for $28 per share, a premium of more than 100% and a transaction amount of approximately $2 billion. Ambrx is a developer of cancer treatments. The cash transaction presents a premium of 105% to the January 5 close. “We are pleased to enter into this agreement with Johnson & Johnson to advance scientific research to treat cancers with significant unmet need,” said Daniel J. O’Connor, Chief Executive Officer of Ambrx.
©2024 Boursier.com